Suggestions

Market Insights - Page 3

Urea-Cycle-Disorders-Market-Insights

Urea Cycle Disorders Market Poised for Strong Expansion by 2034

According to a recent DelveInsight report, the Urea Cycle Disorders (UCD) market is expected to witness substantial expansion through 2032, driven by increasing disease awareness, improved diagnostics, and a rapidly advancing therapeutic pipeline. The report, titled “Urea Cycle Disorders Market Insights, Epidemiology,
21 January 2026
Chronic Refractory Cough Market
··

Chronic Refractory Cough Market Hits $8.5B in 2024!

The chronic refractory cough (CRC) market is projected to witness substantial growth through 2034, driven by an expanding diagnosed patient population, increasing recognition of chronic cough as a distinct clinical condition, and the shortcomings of currently used off-label therapies. Chronic Refractory Cough
21 January 2026
Geographic Atrophy Market
··

Geographic Atrophy Market Poised for Robust Growth

The global Geographic Atrophy Market is expected to witness substantial growth over the forecast period from 2025 to 2034, fueled by a rising elderly population, increasing disease prevalence, growing demand for disease-modifying treatments, and the advancement of novel therapeutic approaches—particularly complement inhibitor
21 January 2026
Sickle Cell Disease Market

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

The Sickle Cell Disease (SCD) market is projected to experience remarkable growth through 2034, supported by increasing disease prevalence, improving diagnostic awareness, and rapid advancements in disease-modifying and gene-based therapies. According to DelveInsight, the market is expected to expand at a CAGR
20 January 2026
·

Global Pharmaceutical Contract Manufacturing Market Expected to Exceed USD 360 Billion by 2032 | DelveInsight

The pharmaceutical contract manufacturing market is witnessing robust growth, largely fueled by the increasing prevalence of chronic and infectious diseases. This expansion is further supported by the growing demand for biologics and biopharmaceuticals. Additionally, pharmaceutical and biotechnology companies are actively strengthening their
20 November 2025

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

The introduction of novel therapies, including BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), among others, is poised to reshape the myelofibrosis treatment landscape. DelveInsight’s Myelofibrosis Market Insights report includes
19 November 2025
1 2 3 4

    Banner

    Newsletter